[1]杨柳.组织多肽特异性抗原的临床意义[J].国际放射医学核医学杂志,2003,27(5):216-218.
　YANG Liu.Clinical value of tissue polypeptide specific antigen[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(5):216-218.
点击复制

组织多肽特异性抗原的临床意义(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
27
期数:
2003年第5期
页码:
216-218
栏目:
核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Clinical value of tissue polypeptide specific antigen
作者:
杨柳
434000 荆州市, 湖北省荆州市第一人民医院内分泌科
Author(s):
YANG Liu
Department of Endocrinology, Jingzhou First People’s Hospital, Jingzhou 434000, China
关键词:
组织多肽特异性抗原; 恶性肿瘤; 复发
Keywords:
tissue polypeptide specific antigen; malignant tumor; recurrence
分类号:
R446.62
摘要:
恶性肿瘤的复发是患者高死亡率的重要因素之一,提高恶性肿瘤复发的早期诊断,是提高恶性肿瘤患者预后生存率的前提。组织多肽特异性抗原在恶性肿瘤复发的诊断上有着较为突出的优势。
Abstract:
The high recurrence of malignant tumor is one of the important factors in mortality of the can-cer.The way to raise the rate of early diagnosis in recurrence of the malignant tumor is to raise the prognosis of survival rate.The tissue polypeptide specific antigen has its dominance in early diagnosis of the recurrence of the malignant tumor.

参考文献/References:

[1] Rebhandl W, Rami B, Turbull J, et al. Diagnostic value of tissue polypeptide-specific antigen (TPS) in neuroblastoma and Willms’ tumour[J].Br J Cancer,1998,78(11): 1503-1506.
[2] Senapad S, Neungton S, Thirapakawong C, et al. Predictive calue of the combined serum CA125 and TPS during chemotherapy and before second-look laparotomy in epithelial ovarian cancer[J]. Anticancer Res, 2000, 20(2B): 1297-1300.
[3] Van Dalen A, Favier J, Baumgartner L, et al. Prognostic significance of CA125 and TPS levels after chemotherapy in ovarian cancer atients[J]. Anticancer Res, 1999, 19(4A): 2523-2526.
[4] Tempfer C, Hefler L, Haeusler G, et al. Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients[J]. Int J Cancer, 1998, 79(3): 241-244.
[5] Nisman B, Lafair J, Heching N, et al. Evaluation of tissue polypeptide specific antigen, CYFRA21-1 and carcinoem-bryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?[J]. Cancer, 1998, 82(10): 1850-1859.
[6] Ho YJ, Hsieh JF, Tasi SC, et al. Tissue polypeptide specific antigen and squamous cell carcinoma antigen for early prediction of recurrence in lung squamous cell carcinoma[J]. Lung, 2000, 178(2): 75-80.
[7] Slesak B, Harlozinska-Szmyrka A, Knast W, et al. Tissue polyopeptide specific antigen(TPS), a amrker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative studywith CA19-9[J]. Cancer, 2000, 89(1): 83-88.
[8] Polito M, Minardi D, Recchioni A, et al. Serum markers for monitoring of prostatic carcinoma[J]. Prostate, 1997, 33(3): 208-216.
[9] Suzuki S, Furukawa H, Tsuchiya A, et al. Clinical evaluation of serum tissue polypeptide specific antigen in patients with thyroid carcinoma[J]. Thyroid, 1999, 9(9): 921-925.

相似文献/References:

[1]范我.用于肿瘤治疗的放射性药物[J].国际放射医学核医学杂志,2004,28(1):21.
　FAN Wo.Radiopharmaceuticals for tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(5):21.
[2]刘英,陈龙华,巩湘浩,等.VEGF与肿瘤的放射治疗[J].国际放射医学核医学杂志,2003,27(4):183.
　LIU Ying,CHEN Long-hua,GONG Xiang-hao,et al.VEGF and radiation sensibitity[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(5):183.

备注/Memo

备注/Memo:
收稿日期:2003-09-01
作者简介:杨柳(1957-),男,主管技师,主要从事临床核医学研究。
更新日期/Last Update: 1900-01-01